Gilead Sciences Inc

Day range

$155.76 – $157.65

Open

$156.47

Prev close

$157.19

Volume

6.07M

Market cap

$194.91B

Shares out

1.24B

P/E

—

P/S

6.40

P/B

16.48

P/FCF

15.06

ROE

-27.4%

ROA

-6.6%

Debt/Equity

2.22

Div yield

2.09%

As of Oct 22, 2026

• Earnings and performanceAug 4, 2026

  On August 4, 2026, Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced its financial results for the quarter ended June 30, 2026. A copy of the press release is filed as Exhibit 99.1 to this report.

• Debt activityMay 20, 2026

  The Eleventh Supplemental Indenture relates to the Company's issuance of (a) $500,000,000 aggregate principal amount of the Company's 4.250% Senior Notes due 2028, (b) $1,000,000,000 aggregate principal amount of the Company's 4.400% Senior Notes due 2029, (c) $1,000,000,000 aggregate principal amount of the Company's 4.600% Senior Notes due 2031 and (d) $500,000,000 aggregate principal amount of the Company's 4.900% Senior Notes due 2034.

• Shareholder activismMay 4, 2026

  The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes: Votes For 280,044,780, Votes Against 752,716,225.

• Shareholder returnsApr 28, 2026

  on March 6, 2026, Purchaser commenced a tender offer (the "Offer"), to purchase all of the issued and outstanding shares of common stock of the Company at a price per Share of (i) $115.00 per Share (the "Closing Amount"), net to the seller in cash, without interest, subject to any withholding tax, plus (ii) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR, in cash, without interest, and subject to any withholding tax, payable on March 31, 2030.

• Business developmentsFeb 23, 2026

  On February 23, 2026, Parent and the Company issued a joint press release announcing (i) their entry into the Merger Agreement and (ii) the acceptance by the U.S. Food and Drug Administration of the Biologic License Application for anito-cel, the Company's BCMA-targeting ddCAR product candidate being evaluated in patients with relapsed or refractory multiple myeloma.

• VRTXVertex Pharmaceuticals Inc-2.09%
• PFEPfizer Inc.-1.28%
• ABBVABBVIE INC.+0.16%
• MRNAModerna, Inc. Common Stock-1.25%
• MRKMerck & Co., Inc.-1.34%
• AMGNAmgen Inc-1.79%
• REGNRegeneron Pharmaceuticals Inc-1.72%
• LGNDLigand Pharmaceuticals Inc.-1.39%

Days to cover

3.4

Short interest

21.83M

Avg volume

6.5M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
  neutralThe Motley Fool· Oct 23, 2026
• Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
  positiveZacks Investment Research· Oct 22, 2026
• Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
  neutralThe Motley Fool· Oct 22, 2026
• Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
  neutralZacks Investment Research· Oct 21, 2026
• Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Oct 21, 2026